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Abstract
Background: This study demonstrates a critical role in CNS innate immunity of the microglial Toll-like receptor 4
(TLR4) in the induction and maintenance of behavioral hypersensitivity in a rat model of bone cancer pain with the
technique of RNA interference (RNAi). We hypothesized that after intramedullary injection of Walker 256 cells (a
breast cancer cell line) into the tibia, CNS neuroimmune activation and subsequent cytokine expression are
triggered by the stimulation of microglial membrane-bound TLR4.
Results: We assessed tactile allodynia and spontaneous pain in female Sprague-Dawley (SD) rats after
intramedullary injection of Walker 256 cells into the tibia. In a complementary study, TLR4 small interfering RNA
(siRNA) was administered intrathecally to bone cancer pain rats to reduce the expression of spinal TLR4. The bone
cancer pain rats treated with TLR4 siRNA displayed significantly attenuated behavioral hypersensitivity and
decreased expression of spinal microglial markers and proinflammatory cytokines compared with controls. Only
intrathecal injection of TRL4 siRNA at post-inoculation day 4 could prevent initial development of bone cancer
pain; intrathecal injection of TRL4 siRNA at post-inoculation day 9 could attenuate, but not completely block, well-
established bone cancer pain.
Conclusions: TLR4 might be the main mediator in the induction of bone cancer pain. Further study of this early,
specific, and innate CNS/microglial response, and how it leads to sustained glial/neuronal hypersensitivity, might
lead to new therapies for the prevention and treatment of bone cancer pain syndromes.
Background
Bone metastasis-induced pain manifests as sponta-
neous pain, hyperalgesia, and allodynia[1]. Pain severe
enough to compromise their daily lives affects 36%-
50% of cancer patients[2]. To clarify the mechanisms
of bone cancer pain, rat models of bone cancer pain
using breast cancer cells (Walker 256 cell) have been
established[3,4], and Yao et al. [4] revealed that rats
with bone cancer pain were not sensitive to radiant
heat pain.
Bone cancer pain appears to be mechanistically dis-
tinct compared with neuropathic or inflammatory pain
states, where major differences occur in the cellular and
neurochemical changes in the nervous system. There is
a prominent up-regulation of glial cells in the spinal
cord ipsilateral to bone cancer pain [5]. Increasing evi-
dence indicates that glial cell activation in the spinal
cord plays a critical role in the initiation and/or mainte-
nance of pathological pain with various etiologies [6].
With regard to neuropathic pain, several neuron-to-glia
activation signals have been proposed, including frac-
talkine acting via microglial CX3CR1, ATP acting via
the microglial P2X4 receptor, or P2X7 receptor and
proinflammatory cytokines (IL-1b,T N F - a,I L - 6a n d
INF-b) release via the microglial TLR4 receptor [7-9].
TLR4 is a transmembrane receptor protein with extra-
cellular leucine-rich repeat domains and a cytoplasmic
signaling domain. In the central nervous system, TLR4
is predominantly expressed by microglia. It has been
proposed that the TLR4 is the key receptor in the
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LPS and exogenous pathogen [10]. Tanga et al. demon-
strated that sensory neuron damage leads to the release
of such substances and that these stimulate microglial
TLR4 in the spinal cord, initiating microglial activation
[11]. Recently, Bettoni et al. reported that repeated
administration of a potent TLR4 antagonist (FP-1)
resulted in relief of both thermal hyperalgesia and
mechanical allodynia in mice with painful neuropathy
[9]. Direct evidence of TLRs mediating inflammatory
pain is still lacking. Data has accumulated on TLR
expression or effects of TLR ligands on microglial acti-
vation during inflammatory pain. In a rat model of com-
plete Freund’s adjuvant-induced chronic pain, increased
microglial activation, accompanied by upregulation of
TLR4 mRNA expression and release of TNFa, IL-1b,
and IL-6, has been reported [12]. Such findings impli-
cate participation of TLRs in inflammatory pain.
OX42, a microglial cells-specific cellular protein found
in the supporting glial cells of the spinal cord, increased
markedly in bone cancer pain [13]. TLRs are also
expressed on the tumor cell surface, and the incidence
of lung cancer in TLR4 mutant mice is 60% more than
in normal mice [14]. TRL4 also mediates the destruction
of first molar [15] and cranial bones [16]. These data
indicate that TLR4 is closely related to the occurrence
of tumors and bone destruction. Thus, we speculated
that the immune response mediated by the TLR4 signal-
ing pathway might be involved in the induction and
maintenance of bone cancer pain. Blocking the TLR4
signaling pathway could potentiate analgesic effects in
bone cancer pain.
RNA interference (RNAi), an accurate and potent
gene-silencing method, has demonstrated the clinical
potential of synthetic small interfering RNAs (siRNAs)
or short hairpin RNAs (shRNAs) in dental diseases,
eye diseases, cancer, metabolic diseases, and neurode-
generative disorders [17]. RNAi can selectively silence
genes, and is more efficient than traditional antisense
approaches [18]. The purpose of the present studies is
three-fold. First, we assessed glial activation, TLR4 and
cytokine expression, and behavioral hypersensitivity
after Walker 256 cells inoculation in female S-D rats.
Second, we ensured the in vitro effectiveness of the
siRNAs in knocking down TLR4 mRNA. Third, we
tested whether TLR4 blockade by intrathecal injection
of siRNA could reverse well-established bone cancer
pain, and not simply prevent its initial development,
because reversal is the more clinically relevant end-
point. We established a role for TLR4 and CNS innate
neuroimmune activation in the development of beha-
vioral hypersensitivity in a rat model of bone cancer
pain.
Results
Bone cancer pain caused by Walker 256 cells inoculation
Rats with tibia tumors after Walker 256 cells inoculation
displayed both tactile allodynia and spontaneous pain
(Fig. 1A). Before Walker 256 cells inoculation, there
were no significant differences in overall mean baseline
paw withdrawal latency (PWL) to tactile allodynia and
ambulatory score(AS) to spontaneous pain among the
normal group, sham group, and bone cancer pain group
(n = 12, ANOVA2w,P W L ,P=0 . 1 3a n dA S ,P=0 . 3 9 ) .
Initially, ipsilateral tactilea l l o d y n i aw a so b s e r v e di nt h e
sham and cancer pain groups after inoculation, but by
two to three days post-surgery, thresholds in both
groups returned to the baseline. In contrast, six days
after inoculation, marked decreases in the PWL to tac-
tile allodynia were observed in more than 90% of the
tumor-bearing rats compared with sham-injected con-
trols (ANOVA2w, P < 0.05, pos-hoc Bonferroni); at the
same time, the ambulatory score began to rise (ANO-
VA2w, P < 0.05, pos-hoc Bonferroni). Subsequently, the
PWL progressively decreased and the ambulatory score
progressively increased in the tumor-bearing group
(ANOVArm, P < 0.01, pos-hoc Bonferroni).
Radiography of the left tibia showed 18 days’ tumor-
bearing proximal epiphysis of the tibiae, there was bilat-
eral cortical bone damage and large bone defects (Fig.
1B). Histological studies showed that the bone marrow
cavity was full of tumor cells and that the cortical bone
was destroyed (Fig. 1C).
TLR4 expression increases in the bone cancer pain model
The relative levels of spinal TLR4 mRNA were signifi-
cantly higher (n = 4, ANOVA1w, P < 0.01, post hoc
Dunnett testing) in bone cancer pain rats than in sham
rats, on the sixth day after inoculation (Fig. 2B). This
suggests that expression of TLR4 mRNA was up-regu-
lated by the induction of bone cancer. At the protein
level, data from several western blot experiments
revealed a significant up-regulation of TLR4(n = 4,
ANOVA1w, P < 0.01, post hoc Dunnett testing) on the
sixth day after inoculation (Fig. 2A, C). The protein
levels further increased at 12 and 18 days after inocula-
tion compared with sham-injected controls and normal
rats, respectively. These data suggest that TLR4 expres-
sion was significantly up-regulated in the bone cancer
pain model caused by Walker 256 cells inoculation.
Microglial activation and proinflammatory cytokine
expression increases in the bone cancer pain model
A two- to three-fold increase in the mRNA expression
levels of microglial activation markers CD11b and CD14
was observed in bone cancer pain rats at days 6 and 12
after inoculation (n = 4, ANOVA1w,P<0 . 0 1 ,p o s th o c
Dunnett testing). CD11b mRNA expression was also
higher at day 18 after inoculation relative to the normal
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nett testing). The bone cancer pain group also showed
significant up-regulation proinflammatory cytokines
mRNA (IL-6, IL-1b,T N F - a,a n dI N F - b)( n=4 ,A N O -
VA1w, P < 0.01, post hoc Dunnett testing), starting at
day six after inoculation for IL-1b and TNF-a (P <
0.05), and starting at day 12 after inoculation for IL-6
and INF-b (P < 0.01) (Fig. 3).
Identification of optimal siRNAs for knockdown of TLR4
in cell culture
To assure the effectiveness of the siRNA sequences for
intrathecal injection, the ability of these siRNAs to
knockdown TLR4 mRNA was determined in vitro.T h e
TLR4 siRNA pool (2 μg) reduced TLR4 mRNA by 83%
(siRNA439), 61% (siRNA312), 55% (siRNA1495), and 53%
(siRNA2062), respectively, compared with a vehicle-trea-
ted group, 24 h after transfection in a microglial cells
line (HAPI). This effect was not seen with scrambled
duplexes (Fig. 4B). In addition to measuring the effect of
the siRNA treatment on TLR4 mRNA, we also deter-
mined their effect TLR4 protein expression 48 h after
transfection, by western blot analysis. TLR4 protein
expression was significantly reduced following treatment
with TLR4 siRNA compared with mismatched siRNA
treatment (Fig. 4A,C). The most effective siRNA for
knocking down TLR4 expression was siRNA439(n = 4,
ANOVA1w, P < 0.001, post hoc Dunnett testing).
Intrathecal TLR4 siRNA439 attenuates bone cancer pain
in the rat model
In the siRNA-treated IBCP group, the PWTs were sig-
nificantly higher and the ambulatory scores were signifi-
cantly lower than those observed in mismatch siRNA-
and vehicle-treated rats (n = 10, ANOVA2w, P < 0.01,
pos-hoc Bonferroni), and there were no significant dif-
ferences compared to normal rats (ANOVA2w,P W T ,P
= 0.93 and AS, P = 0.3) (Fig. 5A, B). No significant dif-
ference was observed between mismatch siRNA- and
vehicle-treated rats, which indicated that intrathecal
injection of TLR4 siRNA439 could prevent the initial
development of bone cancer pain. In the siRNA-treated
W B C Pg r o u p ,t h eP W T sw e r es i g n i f i c a n t l ye l e v a t e d
compared with the mismatch siRNA- and vehicle-trea-
ted rats (n = 10, ANOVA2w, P < 0.01, pos-hoc Bonfer-
roni), but still lower than in normal rats (P < 0.05) (Fig.
5C, D). Meanwhile, spontaneous pain was attenuated
compared with mismatch siRNA- and vehicle-treated
rats(n = 10, ANOVA2w, P < 0.01, pos-hoc Bonferroni).
However, the ambulatory score was still higher than
normal rats (P < 0.05), which indicated that intrathecal
injection of TLR4 siRNA439 could alleviate, but not
reverse, well-established bone cancer pain.
Attenuation of TLR4 expression by siRNAs
The TLR4 mRNA levels in the L4~6 lumbar spinal cord
from mismatch siRNA- and vehicle- treated bone cancer
Figure 1 A rat model of bone pain from metastatic bone cancer. (A) Rats with tibia tumors after Walker 256 cells inoculation displayed both
tactile allodynia and spontaneous pain. The PWL progressively decreased and the ambulatory score progressively increased on days 6 (n = 12,
ANOVA2w, P < 0.05 pos-hoc Bonferroni, df = 2, F = 1.07), 9, 12, 14, 16, 18, and 21 (ANOVA2w, P < 0.01, df = 2, F = 1.13) after inoculation (AI) in
the tumor-bearing group compared with sham-injected controls and normal rats. Results are given as means ± S.D, *p < 0.05 **P < 0.01 vs.
normal group;
▲p < 0.05
▲▲ p < 0.01 vs. sham group. (B) Radiographs of the left tibiae 18 days after inoculation with Walker 256 cells and the
right normal tibiae. There was bilateral cortical bone damage and large bone defects at the 18 days’ tumor-bearing proximal epiphysis of the
tibiae. (C) HE staining of normal (upper panel) and 18 days of tumor-bearing (lower) proximal epiphysis of the tibiae. Note that tumor cells were
densely packed in the marrow cavity and induced the destruction of trabeculae. Arrows indicate tumor cells. Bar = 1 mm in B and 40 μmi nC .
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in WBCP group, n = 4) relative to that of normal rats.
TLR4 siRNA439 treatment caused a significant decrease
(58% ± 8 in IBCP group (Fig. 6A), 43% ± 7 in WBCP
group (Fig. 6B) (n = 4)) in the TLR4 mRNA level com-
pared with that in normal rats.
At the protein level, whether in the IBCP group (Fig.
6C, E) or in the WBCP group (Fig. 6D, F), data from
several western blot experiments revealed a significant
up-regulation of the TLR4 (n = 4, ANOVA1w,P<0 . 0 1 ,
post hoc Dunnett testing) protein in mismatch siRNA-
and vehicle-treated bone cancer pain rats relative to that
from normal rats. TLR4 siRNA439 treatment caused a
significant decrease (n = 4, ANOVA1w, P < 0.01, post
hoc Dunnett testing) relative to the level in mismatch
siRNA- and vehicle-treated bone cancer pain rats, and a
significant decline compared to normal rats(P < 0.05) in
the IBCP group.
siRNA-mediated knockdown of TLR4 leads to decreased
bone cancer pain-induced microglial activation and
proinflammatory cytokine expression
Decreased expression of TLR4 was coincident with
decreased expression of the microglial activation mar-
kers CD11b (48% in IBCP group; 39% in WBCP group)
Figure 2 TLR4 expression increases in the bone cancer pain model. (B) Real-time quantitative RT-PCR analyses of mRNA temporal
expression of TLR4 in rat lumbar spinal cord. The relative levels of spinal TLR4 mRNA significantly increased on days 6, 12 and18 (n = 4,
ANOVA1w, P < 0.01, post hoc Dunnett testing, df = 3, F = 1.17) after inoculation (AI) in bone cancer pain rats compared with sham-injected
controls and normal rats. The level of gene expression was calculated after normalizing against b-actin in each sample and is presented as
relative mRNA expression units. (A, C) The protein level of TLR4 detected by western blotting analysis in spinal cord. A significant up-regulation
of TLR4 protein level (n = 4, ANOVA1w, P < 0.01, post hoc Dunnett testing, df = 3, F = 1.06) on the sixth day AI. The protein levels further
increased at 12 and 18 days (P < 0.01) after inoculation compared with sham-injected controls and normal rats, respectively. Each data point
represents at least three independent experiments. Values are presented as mean ± SEM. *P < 0.05, **P < 0.01 vs. normal group;
▲P < 0.05,
▲▲P
< 0.01 vs. sham group;
#P < 0.05,
##P < 0.01 vs. 6 day AI;
◆P < 0.05,
◆◆P < 0.01 vs. 12 day AI.
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hoc Dunnett testing). The decrease in TLR4 also led to
a significant decrease in proinflammatory cytokines, i.e.,
TNF-a (31%; 20%), IL-1b (35%; 33%), IL-6 (16%; 31%),
and INF-b (16%; 58%) compared with rats treated with
vehicle or the mismatch siRNA (Fig. 7).
Discussion
The data presented herein demonstrate a key role for
microglial TLR4 in the induction and maintenance of
behavioral hypersensitivity in rodent models of bone
cancer pain. Our data also shows that transcription of
the microglial activation markers, CD11b and CD14,
was significantly elevated at the initiation phase of beha-
vioral hypersensitivity, and moderately increased at the
maintenance phase. These results suggest that microglia
are involved in the induction and maintenance of beha-
vioral hypersensitivity in rodent models of bone cancer
pain, and are not just involved in the initiating phase, as
in neuropathic pain and inflammatory pain [19,20].
The present study successfully established a female rat
model of bone pain from metastatic bone cancer. What
is in some ways unique about bone cancer pain is that
the inflammation, tumor-released products, and tumor-
induced injury to primary afferent neurons can simulta-
neously drive the chronic pain state [21]. There is a pro-
minent up-regulation of glial cells in the spinal cord,
ipsilateral to bone cancer pain, and a growing body of
evidence suggests that glial cells in the spinal cord play
an important role in pain facilitation [22]. A recent
report shows that a proliferative burst of glial cells
occurs in the ipsilateral dorsal horn following peripheral
nerve injury, and that the majority of dividing cells were
microglia [23]. The time course of microglia prolifera-
tion closely correlated with the development of neuro-
pathic pain, suggesting an important link between
microglia activation and pathogenesis of pain hypersen-
sitivity. Although the signals that induce microglial pro-
liferation in response to nerve injury remain
incompletely clarified, it has been recently reported that,
among the different receptors expressed by microglia,
the TLRs, specifically TLR2 and TLR4, are a likely route
for microglia activation after nerve injury and play a
pivotal role in driving pain hypersensitivity[9]. Our data
showed that the spinal microglial activation markers
mRNA, TLR4 mRNA and TLR4 protein expression
were significantly elevated in the rat model of bone can-
cer pain. Meanwhile, a report revealed that TLR4-defi-
cient mice have reduced bone destruction following
mixed anaerobic infection [15], which suggests that
TLR4 is involved in bone cancer-induced pain percep-
tion. In a model of neuropathic pain, spinal microglia
TLR4 mRNA expression is also increased after L5 nerve
transection in rats [24]. TLR4-knockout and point
mutant mice developed less neuropathic pain, showed
reduced glial activation, and strongly decreased expres-
sion of pain related cytokines [24]. These data shed light
on the mechanistic link between microglial TLR4 activa-
tion and behavioral hypersensitivity.
This is further evidenced by the present study’sf i n d -
ing that functional knockdown of the TLR4 gene by
RNAi significantly inhibited bone cancer-induced beha-
vioral hypersensitivity. Consistent with the behavioral
test, the real-time RT-PCR study and western-blot ana-
lysis demonstrated that TLR4 significantly suppresses
spinal TLR4 mRNA and protein expression during bone
cancer pain. These data indicate that TLR4 is involved
in the spinal transmission and processing of noxious
inputs from the peripheral cancer area and facilitates
bone cancer hyperalgesia. In the model of neuropathic
pain, TLR4 antisense oligonucleotide treatment can sig-
nificantly attenuate the behavioral hypersensitivity [24].
Repeated administration of a potent TLR4 antagonist
(FP-1) could also relieve thermal hyperalgesia and
mechanical allodynia in mice with painful neuropathy
[9]. These data indicate that TLR4 is not only involved
in neuropathic pain, but also in bone cancer pain.
Figure 3 Microglial activation and proinflammatory cytokine
expression increases in the bone cancer pain model. Real-time
quantitative RT-PCR analyses of the temporal expression of
microglial activation markers (CD11b, CD14) and proinflammatory
cytokines (IL-6, IL-1b, TNF-a, and INF-b) mRNA in rat lumbar spinal
cord. The mRNA expression levels of CD11b and CD14 significantly
increased in the bone cancer pain group at six days AI and 12 days
AI (n = 4, ANOVA1w, P < 0.01, post hoc Dunnett testing, df = 3, F =
0.98). CD11b mRNA expression was also higher at 18 days AI (P <
0.05). The bone cancer pain group also showed significant up-
regulation IL-6, IL-1b, TNF-a, and INF-b mRNA relative to the normal
and sham group(n = 4, ANOVA1w, P < 0.01, post hoc Dunnett
testing, df = 3, F = 1.11), starting at day six after inoculation for IL-
1b and TNF-a (P < 0.05), and at day 12 after inoculation for IL-6
and INF-b (P < 0.01). Values are presented as mean ± SEM. *P <
0.05, **P < 0.01 vs. normal group;
▲ P < 0.05,
▲▲ P < 0.01 vs. sham
group;
#P < 0.05,
##P < 0.01 vs. 6 days AI;
◆P < 0.05,
◆◆P < 0.01 vs.
12 days AI.
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functional knockdown of TLR4 also reduced spinal
microglial activation, and reduced the expression of
mRNA for spinal proinflammatory cytokines. A previous
study demonstrated that IL-1b was upregulated in a
bone cancer pain rat model and that intrathecal IL-1ra
produced an anti-pain effect in such a model [13,25].
The CNS innate immune response includes rapid activa-
tion of immune effectors cells and the release of proin-
flammatory cytokines, such as TNF-a,I L - 1b,I L - 6 ,a n d
IFN-b, through the activation of TLR4-MyD88-depen-
dent or -independent pathways [26]. Furthermore, the
expression of proinflammatory cytokines by activated
glia after the injection cancer cells into the tibia has
been shown to be a major factor contributing to the
establishment of behavioral hypersensitivity [27]. As
shown in the present study, the knockdown of TLR4
expression leads to attenuation of behavioral hypersensi-
tivity, decreased glial activation, and decreased expres-
sion of proinflammatory cytokines. Thus, it is very
important that TLR4 provides a mechanistic link
between microglial activation, innate immunity, and the
initiation of behavioral hypersensitivity in the rat model
of bone cancer pain.
Like many chronic pain states, bone cancer pain
becomes more severe with disease progression, requiring
higher doses of analgesics to control the pain[28]. In the
present report, we show that intrathecal TLR4 siRNA
could prevent bone cancer-induced tactile allodynia and
spontaneous pain at an early stage of tumor growth.
However, at the late stage, intrathecal TLR4 siRNA can
only attenuate, but not completely block, well-estab-
lished bone cancer pain. This finding suggests that
TLR4 is the main mediator in the induction of bone
Figure 4 Molecular down-regulation of TLR4 mRNA and protein upon treatment with siRNA. (B) TLR4 mRNA levels in microglial cells line
(HAPI), normalized to b-actin, were significantly reduced in TLR4 siRNA (SITLR4) versus mismatch siRNA- and vehicle-treated cells 24 h after
transfection. siRNA439 was the most effective at knocking down TLR4 expression(n = 4, ANOVA1w, P < 0.001, post hoc Dunnett testing, df = 3, F
= 1.08). (A) The TLR4 protein levels detected by western blotting analysis in HAPI 48 h after transfection, normalized to b-actin. (C) TRL4 protein
levels were significantly reduced following treatment with TLR4 siRNA (SITLR4) compared with vehicle or mismatch siRNA treatment. Each data
point represents at least three independent experiments. Values are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle-
treated cells;
▲P < 0.05,
▲▲P < 0.01,
▲▲▲P < 0.001 vs. mismatch siRNA-treated group.
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significantly higher and the ambulatory scores were significantly lower than those observed in mismatch siRNA- and vehicle-treated rats(n = 10,
ANOVA2w, P < 0.01, pos-hoc Bonferroni, df = 4, F = 1.02), and there were no significant differences compared to normal rats. This indicated that
intrathecal injection of TLR4 siRNA439 (SITLR4) could prevent the initial development of bone cancer pain. (C, D) In the siRNA-treated WBCP
group, the PWTs were significantly elevated compared with the mismatch siRNA- and vehicle-treated rats(n = 10, ANOVA2w, P < 0.01, pos-hoc
Bonferroni, df = 4, F = 0.96), but still lower than in normal rats (P < 0.05) Meanwhile, spontaneous pain was attenuated compared with
mismatch siRNA- and vehicle-treated rats(n = 10, ANOVA2w, P < 0.01, pos-hoc Bonferroni, df = 4, F = 1.05). However, the ambulatory score was
still higher than in normal rats (P < 0.05), which indicated that intrathecal injection of TLR4 siRNA439 (SITLR4) could alleviate, but not reverse,
well-established bone cancer pain. Values are presented as mean ± SEM. *P < 0.05, **P < 0.01 vs. normal group;
▲ P < 0.05,
▲▲P < 0.01 vs.
vehicle-treated group;
#P < 0.05,
##P < 0.01 vs. bone cancer pain group;
◆P < 0.05,
◆◆P < 0.01 vs. mismatch siRNA-treated group. Arrows indicate
the siRNA injection times.
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receptors to be involved in maintaining the pain state
[29,30]. These might include bradykinin, P2X3, TRPV1,
and prostaglandin receptors, acid-sensing ion channel 3
and voltage-gated sodium channels, and unique glial/
neuronal signals like fractalkine. Thus, our results
underscore the complexity of CNS cascades and media-
tors that may underlie neuronal sensitization, the patho-
logical manifestation of cancer pain.
In vivo delivery of siRNAs into the central nervous
system is complicated by the fact that oligonucleotides
do not efficiently cross the blood-brain barrier. Recently,
chemical modifications of siRNAs have become essential
for achieving high levels of gene silencing, enhancing
plasma stability, and increasing in vivo potency, com-
bined with a low degree of undesired effects [31]. The
present study applied RNAi technology that was
improved in two ways: (i) chemical modification of the
siRNA. The introduction of certain constituents, such as
fluorine, into the ribose 2’ position of the primers ren-
ders siRNAs more resistant to nuclear acid enzymes. In
addition, the 3’-end of the siRNA antisense strand has
the special role of identification of the target mRNA,
and chemical modification at the 3’-end of the antisense
strand will lead to a significant increase in interference.
Therefore, we modified our siRNAs with one 2’-FU sub-
stitution at the 3’-end of the sense strand, but left the
antisense chain unmodified, by which we hoped for
enhanced nuclease resistance combined with good speci-
ficity. (ii) Application of an appropriate delivery system.
We applied in vivo jetPEI™ (polyethyleneimine, PEI) as
the siRNA delivery system. PEI is a cationic polymer
nanoparticle that, compared with liposomes or viral vec-
tor, can decrease cytotoxicity, and can avoid potential
vector immunogenicity and tumorigenicity, when used
as an siRNA delivery system. Growing evidence indi-
cates that PEI-siRNA is an ideal tool for inhibiting spe-
cific gene expression [31].
Figure 6 Attenuation of TLR4 expression by Intrathecal TLR4 siRNA439. (A, B) The TLR4 mRNA levels in the L4~6 lumbar spinal cord from
mismatch siRNA- and vehicle- treated bone cancer pain rats were higher in IBCP group (A) and in WBCP group (B) (n = 4, ANOVA1w, P < 0.01,
post hoc Dunnett testing, df = 3, F = 1.12)relative to that of normal rats. TLR4 siRNA439 (SITLR4) treatment caused a significant decrease in IBCP
group, and in WBCP group in the TLR4 mRNA level compared with that in normal rats (P < 0.01). (C, D, E, F) Data from several western blotting
experiments revealed a significant up-regulation of TLR4 (n = 4, ANOVA1w, P < 0.01, post hoc Dunnett testing, df = 3, F = 1.16) protein in
mismatch siRNA-and vehicle- treated bone cancer pain rats relative to that from normal rats, whether in the IBCP group (C, E) or in the WBCP
group (D, F). TLR4 siRNA439 treatment caused a significant decrease (n = 4, ANOVA1w, P < 0.01, post hoc Dunnett testing, df = 3, F = 0.96)relative
the level in mismatch siRNA-and vehicle- treated bone cancer pain rats, and a significant decline compared to normal rats (P < 0.05) in the IBCP
group (C, E). Values are presented as mean ± SEM. *P < 0.05, **P < 0.01 vs. normal group;
▲ P < 0.05,
▲▲ P < 0.01 vs. vehicle-treated group;
◆P<
0.05,
◆◆P < 0.01 vs. mismatch siRNA-treated group.
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siRNA439. In both IBCP group and WBCP group, Real-time quantitative RT-PCR analyses revealed a significant down-regulation of two microglial
activation markers, CD14 and CD11b compared with mismatch siRNA- and vehicle-treated rats(n = 4, ANOVA1w, P < 0.01, post hoc Dunnett
testing, df = 3, F = 1.08). Proinflammatory cytokines mRNA expression was also significantly down-regulated, i.e., IL-1b (P < 0.01), TNF-a (P <
0.05), IL-6 (P < 0.01), and INF-b (P < 0.01) in the WBCP group; IL-1b (P < 0.01), and TNF-a (P < 0.01) in the IBCP group compared with rats
treated with vehicle or the mismatch siRNA. Values are presented as mean ± SEM. *P < 0.05, **P < 0.01 vs. normal group;
▲ P < 0.05,
▲▲ P < 0.01
vs. vehicle-treated group;
◆P < 0.05,
◆◆P < 0.01 vs. mismatch siRNA-treated group.
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Our results provide evidence for a role of the key innate
immune receptor, TLR4, in a rat model of bone cancer
pain. The ability of TLR4 to activate a pathway leading
to central sensitization and behavioral hypersensitivity
could provide an opportunity for regulating glial activa-
tion, and thus, alleviating chronic pain, such as bone
cancer pain.
Experimental procedures
Animals
Sprague-Dawley rats (150-180 g) provided by the
Experimental Animal Center of Soochow University,
were kept under a 12 h/12 h light-dark cycle regime,
with free access to food and water. All surgical and
experimental procedures were reviewed and approved
by the Animal Care and Use Committee of the Soochow
University. Animal treatments were performed accord-
ing to the Guidelines of the International Association
for the Study of Pain (Zimmermann, 1983).
Intrathecal Catheterization
Five days before intra-tibial injection of Walker256 cells,
under anesthesia with pentobarbital sodium (40 mg/kg,
i.p.), a polyurethane intrathecal catheter with an inner
diameter of 0.3 mm and an outer diameter of 0.6 mm
(R-ITC, Pittsburgh, PA) was inserted 5 mm cephalad
into the rat lumbar subarachnoid space at the L4-L5
intervertebrae. The tip of the catheter was located near
the lumbar enlargement of the spinal cord, to adminis-
ter the drugs intrathecally, according to the modification
of a method described previously [32]. The catheter was
tunneled subcutaneously and externalized through the
skin in the neck region. The volume of dead space of
the intrathecal catheter was 10 μl. To avoid occlusion of
the catheter, 10 μl of normal saline was injected via a
catheter on alternate days until the end of the experi-
ment. Three days later, 2% lidocaine (10 μL) was
injected intrathecally to rats that showed no impaired
movement, and animals that showed lower limb paraly-
sis within 30 s indicated successful catheterization.
Bone cancer model
Walker 256 cells injection protocol was performed as
described previously [33]. In brief, under anesthesia with
pentobarbital sodium (40 mg/kg, i.p.), rats were fixed,
and the left tibia was prepared for surgery. A skin inci-
sion was made parallel to the tibia to expose the tibial
plateau. A needle was then inserted into the medullary
canal to create a pathway for the Walker 256 cells. A
depression was then made using a microinjector. Sham
animals (n = 10) were generated with an injection of 5
μl of saline into the intramedullary space of the tibia,
whereas Walker 256-injected animals (n = 10) were
injected with media containing 10
5 Walker 256 cells in
5 μl. For all animals, the injection site was sealed with a
medical glue to confine the cells within the intramedul-
lary canal, followed by irrigation with sterile water
(hypotonic solution). Finally, incision closure was
achieved using the medical glue.
Behavioral studies
Tactile allodynia
Tactile allodynia was assessed by using von Frey fila-
ments (Stoelting, Wood Dale, IL). Animals were placed
in individual plastic boxes (20 cm × 25 cm × 15 cm) on
a metal mesh floor and allowed to acclimatize for 30
min. The filaments were presented, in ascending order
of strength, perpendicular to the plantar surface with
sufficient force to cause slight bending against the paw
and held for 6-8 s. Brisk withdrawal or paw flinching
were considered as positive responses. The paw withdra-
wal threshold (PWT) was determined by sequentially
increasing and decreasing the stimulus strength (the
“up-and-down” method), and the data were analyzed
using the nonparametric method of Dixon, as described
by Chaplan et al. [34].
Spontaneous pain
Spontaneous pain was evaluated by ambulatory score in
the tumor-injected hind limb. The scoring of each ani-
mal was characterized as follows: normal activities (0);
mild claudication (1); moderate claudication (2); severe
claudication (3); and disuse (4). All of the behavioral
data were obtained using at least twelve animals for
each time point or group.
Assessing the extent of bone destruction
Radiology
To confirm cancer development in the tibia, rats were
X-rayed six, 12, and 18 days after surgery. Anaesthetized
rat hind limbs were placed on X-ray film (Kodak, Ita1v)
and exposed to an X-ray source (Emerald 125) for 1/20
s at 40 KVP. The radiographic images were visually
quantified using the scale developed by Schwei et al
[35].
Histochemical staining
After demineralizing in EDTA (10%) for 2-3 weeks, the
tibiae were embedded in paraffin, and 10 μms e c t i o n s
were cut and stained with Harris’ hematoxylin and eosin
(HE) to verify cancer cell infiltration and bone
destruction.
Small interfering RNA (siRNA) constructs
Four different siRNA duplexes targeting the S-D rat
TLR4 were selected using standard siRNA design rules.
Additionally, a scrambled sequence was designed as a
mismatch control. BLAST search of nucleotide
sequences in the GenBank database showed no substan-
tial homology with other genes. The sequences of these
five siRNA constructs are shown in Table 1. All siRNA
duplexes were chemically synthesized by Genepharma
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a n ds t o r e da t- 8 0 ° C ,a tac o n c e n t r a t i o no f2 0 0μMi n
annealing buffer as previously described [36].
In vitro analysis of siRNA-mediated knock down of
TLR4 inHAPI cells
Microglial cells (HAPI cell line; a gift from Dr. Si JH,
NanTong University) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum, penicillin (100 U/ml), and
streptomycin (100 μg/ml). One day before transfection,
the cells were trypsinized and resuspended in DMEM
without antibiotics, and plated into a 24-well plate at a
density of 1.5 × 10
5 cells per 0.6 ml per well. Cells were
transfected with 2 μg of siRNA/Lipofectamine™ 2000
(Invitrogen, Carlsbad, CA) complexes in 1:3 ratio (w/v)
per well (four gene-specific siRNAs or a mismatch con-
trol siRNA). Forty-eight hours after transfection, the
cells were harvested for western blot analysis of the
level of knockdown proteins by the siRNAs. For target-
ing and detection of the mRNA levels, after 24 hr of
transfection, RNA was isolated from the cells using
RNAqueous™ -96 (Ambion), and subjected to Quantita-
tive RT-PCR.
siRNA delivery
Four days after cancer cells injection, rats showing gen-
eral good health with no signs of distress and no
marked weight loss were selected for RNA delivery. The
rats were divided into siRNA, mismatch RNA, and vehi-
cle groups, with at least six rats per group. To increase
the intracellular stability of the siRNAs, siRNAs for vivo
administration were modified with one stabilizing 2’-FU
substitution at the 3’-end of the sense strand. siRNA or
mismatch RNA complexes were prepared immediately
prior to administration by mixing the RNA solution
(200 μM in annealing buffer) with a transfection
reagent, in vivo jetPEI™ (Polyplus, French), in a ratio of
1:4 (w:v). At this ratio, the final concentration of RNA
as an RNA/lipid complex was 2 μgi n1 0μl. siRNA or
mismatch RNA, or in vivo jetPEI™ alone (defined as
vehicle) in 10 μl was delivered to the lumbar region of
the spinal cord via the i.th. catheters. The catheters
were flushed with 10 μl of sterile saline. Injections were
given daily for three consecutive days. Nociceptive
testing and tissue harvesting were carried out 24 hr
after the last injection.
Real-time RT-polymerase chain reaction (RT-PCR)
HAPI Cells were rinsed twice with PBS and treated with
the RNA extraction reagent Trizol (Invitrogen); Lumbar
spinal cords (L4 and L5), taken from the rats and pre-
served in RNA later (Ambion), were homogenized using
a Tissuelyser (MM300, Qiagen) with a single 6.5 mm
stainless steel ball per sample. Total RNA was isolated
from the homogenate using an RNeasy Plus Mini Kit
according to the manufacturer’s recommended protocol.
Total RNA was precipitated by centrifugation at 20,000
× g for 15 min at 4°C, washed twice with ethanol, and
quantified by UV spectrophotometry at 260 nm. Only
RNA with a 260/280 ratio >2.0 was used for the reverse
transcription (RT) reaction. TaqMan primers and probes
were designed with PrimerExpress software (ABI). The
sequences of the rat primers and probe for TLR4 (Gen-
Bank accession # NM_019178), two microglial activation
markers: CD11b (NM_012711) and CD14
(NM_021744), and cytokine:IL-6 (NM_012589), IL-1b
(NM_031512.2), TNF-a (NM_012675.2), and INF-b
(NM_019127.1) are shown in Table 2.
Quantitative PCR was carried out using MJ Research
PTC-100 with TaKaRa Ex Taq R-PCR Version 2.1
(TaKaRa, Dalian, China) and Evagreen™ (Biotium, Inc.,
CA, United States) according to manufacturer’s instruc-
tions. The PCR reactions were prepared using the com-
ponents from the Platinum qRT-PCR kit and assembled
according to the manufacturer’s instructions (Qiagen).
The final concentrations of the primers and probe in
the PCR reactions were 200 nM and 100 nM, respec-
tively. The fluorogenic probes were labeled with 6-car-
boxyfluorescein (6FAM) as the reporter and 6-carboxy-
4,7,2,7’-tetramethylrhodamine (TAMRA) as a quencher.
Each 10 μl PCR reaction contained 2 μl (10 ng) of total
RNA. Six replicates of each RT-PCR reaction were per-
formed in a 384-well plate according to the following
protocol: 1 cycle for 10 min at 50°C, followed by a 15-
min cycle at 95°C, followed by 45 cycles at 95°C for 15 s
and 60°C for 1 min. A eukaryotic 18S rRNA endogenous
control probe/primer set (ABI) was used as an internal
control for RNA quality.
Table 1 SiRNA oligo
Gene Primer forward Primer reverse
MC UUCUCCGAACGUGUCACGUTT ACGUGACACGUUCGGAGAATT
312 CCUUGGUACUGACAGGAAATT UUUCCUGUCAGUACCAAGGTT
439 GCUUAUAUCCUUAAAGAAATT UUUCUUUAAGGAUAUAAGCTG
1495 GGAUCUUUCUAAAUGCCAATT UUGGCAUUUAGAAAGAUCCAG
2062 CGAGCUGGUAAAGAAUUUATT UAAAUUCUUUACCAGCUCGTT
Sequences of short interfering RNA (siRNA) constructs used in this study. In addition to a mismatch control siRNA construct, foure different siRNA duplexes were
designed that targeted the coding region of the rat TLR4 mRNA (NM_019178).
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HAPI Cells (rinsed twice with PBS), Lumbar spinal
cords (L4 and L5) taken from the rats, cells, and tissue
samples were homogenized in lysis buffer (pH 7.9:
HEPES 10 mmol/L, Na3VO4 1 mmol/L, MgCl2 1.5
mmol/L, KCl 10 mmol/L, NaF 50 mmol/L, ethylenedia-
minetetraacetic acid (EDTA) 0.1 mmol/L, Ethylene gly-
col-bis(beta-aminoethyl ether)-N, N, N’,N ’-tetra acetic
acid (EGTA) 0.1 mmol/L, phenylmethylsulfonyl fluoride
(PMSF) 0.5 mmol/L, dithiothreitol (DTT) 1 mmol/L and
0.02% protease inhibitor cocktail). The homogenates
were incubated for 30 min in ice-cold water with con-
stant agitation and then centrifuged at 13 000 g for 15
min at 4°C. The supernatants were used for Western
blot analysis. Protein concentrations were determined
using the Bradford method [37] and the protein samples
were stored at -80°C.
Protein samples were dissolved in 4 × sample buffer
(Tris-HCl 250 mmol/L, Sucrose 200 mmol/L, DTT 300
mmol/L, 0.01% Coomassie brilliant blue-G, and 8%
sodium dodecyl sulfate, pH 6.8), and denatured at 95°C
for 5 min. Equivalent amounts of protein (40 μg) were
separated using 10% SDS-polyacrylamide gel electro-
phoresis (PAGE) and transferred onto a nitrocellulose
membrane. Membranes were blocked with 5% fat-free
milk solution overnight at 4°C. Samples were probed
with 1:200 dilution of goat polyclonal antibodies against
TLR4 (Santa-Cruz Biotechnology, Inc., Santa Cruz) and
a1 : 5 0 0 0d i l u t i o no fr a b b i ta n t i -g o a tH R P - c o n j u g a t e d
IgG (Huamei Chemical Corp., China). A rat monoclonal
antibody against beta-actin (Sigma) was used as a
loading control. Bands were revealed using an ECL kit
(Pu fei Chemical Corp., Shanghai, China). Scanning den-
sitometry was used for semiquantitative analysis of the
data.
Statistical analysis
All data are presented as mean ± standard error of
mean(S.E.M.). Data from the western-blot and RT-PCR
studies were accomplished using a one-way analysis of
variance (ANOVA1w)f o l l o w e db yp o s th o cD u n n e t t
testing. Data from the nociceptive tests were analyzed
using a two-way ANOVA (ANOVA2w) to analyze differ-
ences between groups at different time points, while
repeated-measures ANOVA (ANOVArm) was used to
evaluate efficiency of treatment along different time
points within groups; pos-hoc Bonferroni’s test was used
to detect significant differences for both ANOVA analy-
sis. A value of p < 0.05 was considered a significant
difference.
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